The FDA has granted priority review to the biologics license application (BLA) for the tumor infiltrating lymphocyte (TIL) therapy lifileucel (LN-144) for the treatment of patients with advanced melanoma who progressed on or after prior anti–PD-1/PD-L1 therapy and targeted therapy.
2023
Biological Patterns in Pediatric Melanoma
In a recent systematic review, researchers sought to evaluate the historical evidence of pediatric melanoma, citing the current evidence’s heterogeneity, particularly regarding melanoma subtypes and prognosis. Furthermore, they intended to highlight major sources of pediatric melanoma heterogeneity, particularly among single patients.
Meaningful End Points for Patients with Metastatic Melanoma
Sunandana Chandra, MD, MS: We’ve talked a lot about different trials that led to the FDA approval of some of these agents. What are some of the more meaningful end points?
Deciding Between Melanoma Therapy Options
Sunandana Chandra, MD, MS: To expound on that a bit more, Dr Pavlick, when you’re thinking of a combination immunotherapy approach for a patient, how do you decide between the 2 combinations that are FDA approved?